Resistance in Gram-Negative Organisms: Studying Intervention Strategies

R-GNOSIS “Resistance in Gram-Negative Organisms: Studying Intervention Strategies" is a European collaborative research project awarded 11.9 Million Euro funding from the European Commission under the Seventh Framework Programme (FP7) for Research and technology.

Lasting 5 years, R-GNOSIS aims at determining the efficacy and effectiveness of cutting-edge interventions to reduce carriage, infection and spread of Multi-Drug resistant Gram-negative Bacteria (MDR-GNB).

The project combines five international clinical studies, all supported by highly innovative microbiology, mathematical modelling and data management.

The five clinical studies will investigate the following interventions:

  • A Point-Of-Care-Testing guided management strategy to improve appropriate antibiotic prescription for uncomplicated UTI in primary care
  • Gut decolonization followed by fecal microbiota transplantation in outpatients with intestinal carriage of MDR-GNB
  • A “test and prescribe” strategy, based on rapid diagnostic testing of faeces for MDR-GNB to optimize antibiotic prophylaxis in colo-rectal surgery
  • Contact Isolation of patients with ESBL-producing Enterobacteriaceae in general hospital wards
  • Three Decolonization strategies in ICUs

Seven laboratories across Europe will perform microbiological analyses, as well as unique quantitative experiments. All information will be integrated by three groups of mathematical modellers into highly innovative models to better understand and predict future trends and effects of interventions.

The studies and analyses proposed in R-GNOSIS will generate a step-change in identifying evidence-based preventive measures and clinical guidance for primary care and hospital-based physicians and health-care authorities, to combat the spread and impact of infections caused by MDR-GNB in Europe.

R-GNOSIS is coordinated by Marc Bonten (UMC Utrecht) and brings together a multidisciplinary team with complementary expertise of clinicians, microbiologists and epidemiologists, infectious disease specialists, caregivers in inpatient care and mathematical modellers. The R-GNOSIS consortium is made of 21 partners from 9 countries which include United Kingdom, Denmark, Germany, Netherlands, Belgium, France, Spain, Switzerland and Israel.

More about R-GNOSIS

Primary Objective

To develop and evaluate cutting-edge interventions to reduce carriage, infection and spread of Multi-Drug resistant Gram-negative Bacteria (MDR-GNB)

ID Week - 8-12 October 2014 - Philadelphia, USA
ID Week - 8-12 October 2014 - Philadelphia, USA
Location: Philadelphia, USA

IDWeek is the annual scientific meeting where infectious diseases professionals can meet, share experiences, and develop collaborations.

54th ICAAC - 5-9 September 2014 - Washington, DC, USA
54th ICAAC - 5-9 September 2014 - Washington, DC, USA
Location: Washington, DC, USA

ICAAC, the premier conference on antimicrobial agents and infectious diseases, showcases the latest-breaking science and lectures from top researchers from around the world. With over 60% of its attendees living outside of the United States, ICAAC provides a rare opportunity to bring together the field’s foremost leaders to discuss the state of infection control and prevention on a global scale.

R-GNOSIS / EvoTAR Review Meeting, January 2014
R-GNOSIS / EvoTAR Review Meeting, January 2014
Location: Madrid, Sapin

In 2014, January 19-22, R-GNOSIS and EvoTAR members gathered in Madrid (Spain) for a joint Review Meeting. This gave all the members a unique opportunity:

  • to share results,
  • to address questions to further understand resistance to antibiotics and develop new drugs and process to limit these resistances.

 This joint meeting was open to R-GNOSIS and EvoTAR members only.